A daily tablet has entered the UK weight-management conversation. But “easier to take” does not mean “casual to use”. Here’s what you need to know before you start searching for an oral GLP-1 weight loss drug.
TL;DR:
- Oral semaglutide, sold as a Wegovy tablet, was approved by the MHRA on 11 June 2026.
- It is authorised for adults with obesity, or overweight plus a weight-related health condition.
- It is taken once daily on an empty stomach, with strict timing around food and drink.
- It is not currently available through the NHS while NICE assesses its place in NHS care.
- It remains a prescription-only medicine. Do not buy it from social media, beauty salons or unregulated sellers.
- Blood testing can provide useful background information for a better conversation with your prescriber or GP, but it does not replace medical care.
What are the new oral GLP-1 weight loss drugs in the UK? The main new option is an oral semaglutide tablet, authorised as Wegovy for weight management in eligible adults. It is prescription-only and is not currently available through the NHS.
What has changed in the UK?
On 11 June 2026, the MHRA approved the first GLP-1 tablet for weight loss and weight management in the UK.
The active ingredient is semaglutide. It acts like a natural hormone called GLP-1, which is released after eating. In simple terms, it helps your brain recognise fullness, reduces hunger and may decrease food cravings.
Think of GLP-1 as a volume control for appetite signals. The medicine does not remove the need for food, movement or follow-up. It changes how strongly those “I’m full” messages are heard.
The tablet is different from:
- Wegovy injection, which is already authorised for weight management.
- Ozempic, which is authorised for type 2 diabetes, not weight loss.
- Rybelsus, an oral semaglutide medicine authorised for type 2 diabetes, not weight loss.
- Mounjaro, which contains tirzepatide and acts on GLP-1 and another hormone pathway.
Always check the exact medicine and licence. Similar names do not mean identical uses.
Who may be eligible?
The MHRA authorisation covers adults in two broad groups:
- Adults with a BMI of 30 or above.
- Adults with a BMI between 27 and 30 who also have at least one weight-related health condition.
Examples include type 2 diabetes, high blood pressure, abnormal blood fats or cardiovascular disease.
BMI is only one part of a health assessment. The NHS explains how BMI is used, including its limits for people with a high level of muscle. This matters if you lift weights, compete in sport or have a naturally muscular build. BMI is more like a rough postcode than a full map of your health.
A prescriber must assess your medical history, current medicines, health conditions and suitability before issuing a prescription. This is not a cosmetic shortcut for people who simply want to lose a small amount of weight.
How is the Wegovy tablet taken?
The approved schedule begins with a low daily dose and increases in stages:
- 1.5 mg once daily
- 4 mg once daily
- 9 mg once daily
- 25 mg once daily
You spend at least one month at each dose level before moving up. Your prescriber should tell you exactly when to increase the dose. Never change it yourself.
The tablet must be:
- Taken whole.
- Taken on an empty stomach after fasting for at least eight hours.
- Swallowed with a small sip of water.
- Followed by at least 30 minutes without food or drink.
This timing matters because eating or drinking too soon can reduce absorption. Imagine trying to catch a train with a narrow departure window. Arrive too late and you miss it. The same basic idea applies here: the tablet needs the right conditions to be absorbed properly.
Follow the patient information leaflet supplied with your medicine. If you miss a dose, feel unwell or are unsure how to restart treatment, contact your prescriber or pharmacist.
NHS access, private access and fake products
MHRA approval means the medicine has been authorised for a particular use. It does not automatically mean the NHS will provide it.
The MHRA states that the oral tablet is not currently available through the NHS. NHS access will depend on further processes, including assessment by NICE and local commissioning decisions.
Private access may be possible after a consultation with a qualified healthcare professional. You should expect checks before a prescription is issued. A legitimate pharmacy should dispense the medicine against a valid prescription.
The MHRA’s guidance on GLP-1 medicines warns against buying these medicines from unregulated sellers.
Avoid:
- Social media sellers.
- Beauty salons offering injections or tablets.
- Products sold as “research” medicines.
- Powder or vial products requiring you to mix your own injection.
- Sellers who do not ask about your medical history.
A tablet may look harmless. It is still a prescription medicine with real effects on your digestion, appetite and metabolism.
Common side effects and serious warning signs
The most common side effects include:
- Nausea.
- Vomiting.
- Diarrhoea.
- Constipation.
- Abdominal discomfort.
These symptoms can affect hydration and food intake, particularly during dose increases. Tell your prescriber if side effects are persistent, severe or stopping you from eating and drinking normally.
Seek urgent medical help if you develop severe, persistent abdominal pain, especially if it travels through to your back and comes with nausea or vomiting. The MHRA has strengthened warnings about acute pancreatitis.
Also seek urgent help if you experience sudden loss of vision or rapidly worsening eyesight. The MHRA describes a very rare possible association between semaglutide and a serious eye condition called NAION in its specific safety update.
Pregnancy, breastfeeding and surgery
Do not take GLP-1 medicines during pregnancy or breastfeeding unless specifically advised by a qualified healthcare professional. The MHRA advises stopping semaglutide at least two months before trying to become pregnant.
Tell your healthcare team if you take semaglutide before surgery or deep sedation. The medicine can slow stomach emptying, which may affect anaesthetic planning.
Should you consider blood testing?
A blood test cannot tell you whether a GLP-1 medicine is right for you. That decision belongs with your prescriber.
However, lab-verified results may help you understand your starting point and prepare for a more useful GP or prescriber conversation. Depending on your circumstances, relevant areas may include:
- Long-term blood sugar markers such as HbA1c.
- Liver markers.
- Kidney markers such as creatinine and eGFR.
- Cholesterol and triglycerides.
- Iron, vitamin B12 or vitamin D.
These results are not a green light or a red light by themselves. They are more like dashboard readings in a car: useful context, but not a substitute for a mechanic’s full assessment.
The Complete Health & Performance Blood Test includes markers covering blood sugar, liver, kidneys, cholesterol, nutrients and hormones. If you only need kidney-related information, the Kidney Health & Renal Function Test is more focused.
For a wider explanation of testing during GLP-1 use, read the Health Hub guide: The GLP-1 Blood Monitoring Guide.
Vitall Check samples are processed by UKAS-accredited partner laboratories using NHS-grade standards. Results are presented in an Insight Report that translates raw laboratory data into clear, plain-English explanations. It does not diagnose you or advise on medication changes.
Your practical checklist
Before considering an oral GLP-1 weight loss drug:
- Confirm the medicine’s licensed use.
- Have a proper consultation with a qualified prescriber.
- Share your full medication and health history.
- Ask how dose increases and follow-up will work.
- Understand the side effects and warning signs.
- Tell your healthcare team before surgery.
- Avoid unregulated sellers.
- Keep your GP informed, including if you receive private treatment.
- Use health data to support an informed arrival, not to self-diagnose.
Takeaway
The new oral GLP-1 option gives eligible adults another route for medically supported weight management. The tablet may be more convenient than an injection, but it still needs careful prescribing, correct timing and proper follow-up.
If you are considering treatment, speak with a qualified prescriber first. Lab-verified blood results may help you and your GP understand your wider health picture, but they are one piece of the puzzle.
FAQ
Q: Is the Wegovy tablet available on the NHS in the UK? A: Not currently. It has MHRA authorisation, but NHS availability depends on NICE assessment and commissioning decisions.
Q: Can I buy oral semaglutide without a prescription? A: No. It is prescription-only. Use a registered prescriber and legitimate pharmacy, and avoid products sold through social media or unregulated websites.
Q: Do I need a blood test before taking an oral GLP-1 medicine? A: Your prescriber will decide what checks are appropriate. Blood testing may provide useful baseline information, but it does not determine suitability or replace a clinical assessment.
Author
Vitall Check Editorial Team
The Vitall Check Editorial Team is dedicated to empowering individuals with evidence-based health information and clear, actionable insights. Every article is researched using peer-reviewed journals and official health resources, reflecting our commitment to the same high standards of accuracy as our laboratory testing services. Our goal is to make proactive wellness accessible, data-driven, and transparent.
Disclaimer: Vitall Check is not CQC registered. The content provided is for general information only, does not provide a diagnosis, and does not replace advice from a qualified healthcare professional. Our services do not include treatment, prescription, or medical advice that falls under CQC-regulated activities. Always consult with your GP or a qualified clinician before making significant changes to your healthcare regimen.
